HCCS Antibodies

Cytochrome c-type heme lyase (HCCS)

Links covalently that the heme group to the apoprotein of cytochrome c.

.

Gene Information

Human
Gene Name:	HCCS
Uniprot:	P53701
Entrez:	3052

Family

Belongs to:
cytochrome c-type heme lyase family

Alternative Names

CCHLDKFZp779I1858; cytochrome c heme-lyase; cytochrome c-type heme lyase; EC 4.4.1.17; holocytochrome c synthase (cytochrome c heme-lyase); holocytochrome c synthase; Holocytochrome c-type synthase; MCOPS7

Molecular Weight

Mass (kDA):
30.602 kDA

Genomic Context

Human
Location:	Xp22.2
Sequence:	X; NC_000023.11 (11111332..11123086)

Subcellular Localizations

Mitochondrion inner membrane. Membrane; Lipid-anchor.

Diseases

• Microphthalmos
• Microphthalmia, Syndromic 7
• Skin Abnormalities
• Carcinoma
• Neoplasms
• Congenital Absence
• Liver Carcinoma
• Liver Neoplasms
• Embryonic Mosaic
• Mitochondrial Diseases
• Malignant Neoplasms
• Monosomy
• Anophthalmos

• Congenital Heart Defects
• Hernia
• Nerve Damage
• Cardiomyopathies
• Diaphragmatic Hernia
• Limb Deformities, Congenital
• Neoplasm Metastasis

Pathways

• Transport
• Neuron Death
• Electron Transport
• Pigmentation
• Oxidative Phosphorylation
• Localization
• Methylation
• Cell Death
• Cell Growth
• Cell Communication

• Angiogenesis
• Pathogenesis
• Heart Development
• Eye Development
• Tissue Homeostasis

PTMs

• Phosphorylation

• Methylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/HCCS

Best Uses Of The HCCS Marker

Boster Bio, an anti-cancer manufacturing company, has developed the HCCS Marker. It is extensively employed in the detection of human cancer cells. It can be used for diagnosing liver cancer. Boster Bio is a global antibody manufacturer. Its antibodies are utilized for clinical trials, biomarker research and a variety of other applications. It is widely utilized by scientists from all over the world.

Boster Bio is an antibody manufacturing company

In 1993, Steven Boster founded Boster Bio which is now located in California. Boster Bio specializes in antibody manufacturing and also offers ELISA kits and molecular biology products that are PCR-related, and signature products. Scientists benefit from the technical assistance offered by the company which is available 24 hours a day and provides online technical assistance. The company makes use of trade secrets that are proprietary to create its own ELISA platform, PicoKine.

qRT-PCR was performed on the Step-One Plus Detection System (Applied Biosystems, USA)

A qRT-PCR carried out on the StepOnePlus Detection System (Applied Biosystem) is an RT-PCR system that operates in real-time. It requires two ml of DNA-diluted reaction mixture and 200nM of each primer. Reactions were carried out under 10 min at 95degC and then analyzed by melting curve analysis.

The quality of a qPCR assay can be measured by comparing it to an established reference method or a certified reference material. This can be used to analyze qualitative data, but it is not suitable to determine accuracy. Methods for reversing have distinct diagnostic specificity and sensitivity, which makes them unsuitable for quantitative evaluation of qPCR tests.

The qRT-PCR technique is extensively utilized to analyze gene expression. Its high sensitivity and specificity makes it a valuable tool for analysis of gene expression. It also requires for genes that are expressed constitutively to compensate for any variations during the test. QRT-PCR is therefore able to be applied to a wide range of samples, ranging from one to hundreds of thousands.

We were able to identify specific primers that are specific to each candidate gene using previously identified control genes from switchgrass. With this approach, we were able to determine the RNA-based gene sequences for 11 possible switchgrass homologues of Cellulose Synthase. Utilizing the default parameters of the Step-One Plus Detection System (Applied Biosystems, USA), we were successful in identifying the most highly expressed gene-specific genes.

As with other methods of DNA detection, qRT-PCR also requires the use of sufficient sequencing data. It is possible to design qPCR tests that can be utilized for any microorganism by increasing the number of sequencing information. By taking advantage of these advantages, qPCR offers the ability to measure high-throughput the targeted DNA sequences. This method also requires less manipulation of the sample.

The qRT-PCR technique is an essential tool for detecting viral pathogens. It is difficult to recognize important veterinary and clinical diseases without a reliable method of testing for viruses in samples. ELISA tests are difficult to locate and have low sensitivity. A powerful tool is RT-qPCR to detect viruses. It offers both high sensitivity and precise.

The reagents used will affect the accuracy of qRTPCR. For instance, in qRT-PCR performed on the Step-One Plus Detection System, the sample must contain at minimum 0.1 percent of the target analyte. Ten duplicates of milk samples were spiked in serial diluting with Campylobacter Jejuni at concentrations between 100 and 105 cells/ml in order to determine the LOD. The LOD value represents 1.56 x 10103 cells/ml. To determine the most exact value, several dilutions were used.

The Step-One Plus Detection System enables the detection of gene expression levels in samples of RNA. The levels of gene expression for the family with similarity in sequence (73B) and the reference gene, GAPDH were determined. The two samples were labeled with gene-specific primers hfam73b-5'-CTCCTGGAGAGCG-3'.

Combining CRP and liver stiffness to identify HCC

The combination of serum CRP and liver stiffness could help to determine AFP levels to help diagnose of HCC. Combining the two could be able to differentiate HCC from LC. This study was funded in part by grants from the National Natural Science Foundation of China (81524031) and the Scientific and Technological Foundation of New Zingxia (xjs).

The LSM is a non-invasive method which measures the stiffness of the liver. It can reveal mild, moderate, or severe stiffness of the liver. The LSM score is correlated with stiffness in the liver and eGFR. The two measures may be used in conjunction or separately to increase the likelihood of HCC. But this is not an absolute method. A successful combination of these two tests needs a high score for liver stiffness, which must be higher than 3.

In the validation cohort, 97 individuals were included. The validation group had 97 patients, whereas the primary cohort comprised 97. However, liver stiffness and the RLV/TFLV ratio were significantly related to CRPHLF and the RLV/BW ratio as well as RLV/BW ratio. It is important to remember that both liver stiffness and CRP should be taken into consideration when making the diagnosis of HCC. To assess their risk of developing cancer, patients must have liver stiffness and CRP tests.

Hepatic cancer is a very violent disease with high death rates. Although serum biomarkers aren't yet universal diagnostic tools, they are considered potential diagnostic tools for early detection. They are non-invasive and convenient and easy to assess and could be used to improve the outlook of patients suffering from HCC. They can be used as an addition to MRI for the detection of HCC.

The use of CRP and stiffness in the liver in conjunction could enable doctors to recognize HCC earlier in the diagnosis process. The combination of these two factors may lead to significant advances in the treatment and diagnosis of this disease. However, this study has not identified a specific cause for HCC. It does not exclude other factors that increase the risk of developing the condition, like HIV infection. It is also important to keep in mind that patients with HCC may have other conditions that contribute to the stiffness.

In addition to the stiffness of the liver, HCC is also diagnosed by the presence of contrast enhancement in CT scans. HCC shows hypervascularity during the arterial phase, and less prominent in the portovenous phase. These findings are based upon pre-treatment evaluation factors such as the amount of lesions and their location. It is also important to consider the presence of lymph node metastasis, liver disease, or major vascular invasion.

While there are numerous potential benefits of combining CRP with stiffness in the liver, a few limitations have to be considered. First, there is no conclusive evidence that suggests that the combination of these two could identify HCC earlier. Furthermore, it does not offer a reliable, accurate diagnosis. However, it could identify HCC in the early stages, thereby decreasing the risk of the recurrence.